<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097641</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-hMSC-ARDS-P2</org_study_id>
    <secondary_id>1U01HL108713-01</secondary_id>
    <nct_id>NCT02097641</nct_id>
  </id_info>
  <brief_title>Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)</brief_title>
  <acronym>START</acronym>
  <official_title>Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael A. Matthay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to
      assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human
      Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress
      Syndrome (ARDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We carried out a randomized, double-blind placebo-controlled trial of allogeneic bone marrow
      derived human mesenchymal stromal cells for treatment of moderate to severe ARDS in 60
      patients, 40 MSC and 20 placebo, in a 2:1 randomization. This trial is the extension of the
      Phase 1 pilot trial (NCT01775774). Patients were followed daily for adverse events through
      day 28, death or hospital discharge, whichever occurs first. Vital status was collected at 6
      and 12 months after study enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2014</start_date>
  <completion_date type="Actual">February 9, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion</measure>
    <time_frame>6 hours</time_frame>
    <description>Within 6 h of study product infusion:
Increase in vasopressor dose to the following values or higher:
Norepinephrine 10 μg/min
Phenylephrine 100 μg/min
Dopamine 10 μg/kg per min
Epinephrine 0.1 μg/kg per min or addition of a third vasopressor
New ventricular tachycardia, ventricular fibrillation or asystole
New cardiac arrhythmia requiring cardioversion
Hypoxaemia requiring an increase in FiO2 of 0·2 or more and an increase in PEEP of 5·0 or more to maintain SpO2 in the target range of 88-95%
Clinical scenario consistent with transfusion incompatibility or transfusion-related infection (eg, urticaria, new bronchospasm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion</measure>
    <time_frame>24 hours</time_frame>
    <description>Within 24 h of study product infusion
• Any cardiac arrest or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety endpoint: Any unexpected severe adverse events in two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PaO2:FiO2 Change From Baseline to Day 3</measure>
    <time_frame>baseline and day 3</time_frame>
    <description>Efficacy endpoint: PaO2:FiO2 change from baseline to day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Injury Score From Baseline to Day 3</measure>
    <time_frame>baseline and day 3</time_frame>
    <description>Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation Index Change From Baseline to Day 2</measure>
    <time_frame>baseline and day 2</time_frame>
    <description>Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Change From Baseline to Day 3</measure>
    <time_frame>baseline and day 3</time_frame>
    <description>Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Death to Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Efficacy endpoint: all-cause mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality to Day 60</measure>
    <time_frame>60 days</time_frame>
    <description>Efficacy endpoint: all-cause mortality at day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-free Days to Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Efficacy endpoint: Number of ventilator-free days to day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-pulmonary Organ-failure-free Days to Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiopoietin 2 Change From Baseline to 6 h</measure>
    <time_frame>baseline and 6 hours</time_frame>
    <description>Biological markers of endothelial injury: angiopoietin 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiopoietin 2 Change From Baseline to 24 h</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Biological markers of endothelial injury: angiopoietin 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 Change From Baseline to 6 h</measure>
    <time_frame>baseline and 6 hours</time_frame>
    <description>Biological markers of inflammation: interleukin 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 Change From Baseline to 24 h</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Biological markers of inflammation: interleukin 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8 Change From Baseline to 6 h</measure>
    <time_frame>baseline and 6 hours</time_frame>
    <description>Biological markers of inflammation: interleukin 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8 Change From Baseline to 24 h</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Biological markers of inflammation: interleukin 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAGE Change From Baseline to 6 h</measure>
    <time_frame>baseline and 6 hours</time_frame>
    <description>Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAGE Change From Baseline to 24 h</measure>
    <time_frame>baseline and 24 hours</time_frame>
    <description>Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Human Mesenchymal Stromal Cells (hMSCs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma-Lyte A (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells</intervention_name>
    <description>Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.</description>
    <arm_group_label>Human Mesenchymal Stromal Cells (hMSCs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma-Lyte A</intervention_name>
    <description>Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.</description>
    <arm_group_label>Plasma-Lyte A (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be eligible for inclusion if they meet all of the below criteria. Criteria
        1-3 must all be present within a 24-hour time period and at the time of enrollment:

        Acute onset (defined below) of:

          1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a
             PaO2/FiO2 ratio &lt; 200 with at least 8 cm H2O positive end-expiratory airway pressure
             (PEEP)

          2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph

          3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.

        Exclusion Criteria:

          1. Age less than 18 years

          2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of
             ARDS

          3. Pregnant or breast-feeding

          4. Prisoner

          5. Presence of any active malignancy (other than non-melanoma skin cancer) that required
             treatment within the last 2 years

          6. Any other irreversible disease or condition for which 6-month mortality is estimated
             to be greater than 50%

          7. Moderate to severe liver failure (Childs-Pugh Score &gt; 12)

          8. Severe chronic respiratory disease with a PaCO2 &gt; 50 mm Hg or the use of home oxygen

          9. Patient, surrogate, or physician not committed to full support (exception: a patient
             will not be excluded if he/she would receive all supportive care except for attempts
             at resuscitation from cardiac arrest)

         10. Major trauma in the prior 5 days

         11. Lung transplant patient

         12. No consent/inability to obtain consent

         13. Moribund patient not expected to survive 24 hours

         14. World Health Organization (WHO) Class III or IV pulmonary hypertension

         15. Documented deep venous thrombosis or pulmonary embolism within past 3 months

         16. No arterial line/no intent to place an arterial line

         17. No intent/unwillingness to follow lung protective ventilation strategy or fluid
             management protocol

         18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory
             ventilation (HFOV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Matthay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16.</citation>
    <PMID>30455077</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <results_first_submitted>January 15, 2019</results_first_submitted>
  <results_first_submitted_qc>March 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2019</results_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michael A. Matthay</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02097641/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From March 24, 2014, to Feb 9, 2017, 1038 patients were screened for eligibility, of whom 975 were excluded, and 63 were randomly assigned to a treatment group. Three patients were not eligible for treatment after randomization and, therefore, 40 patients received human mesenchymal stem cells and 20 patients received placebo.</recruitment_details>
      <pre_assignment_details>Three patients who were randomly assigned to receive human mesenchymal stem cells, were excluded: 2 did not meet baseline stability criteria; 1 patient's PaO2:FiO2 &gt; 200 mmHg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Human Mesenchymal Stem Cells</title>
          <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Plasma-Lyte A</title>
          <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Human Mesenchymal Stem Cells (hMSCs)</title>
          <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
        </group>
        <group group_id="B2">
          <title>Plasma-Lyte A (Placebo)</title>
          <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="17"/>
                    <measurement group_id="B2" value="55" spread="20"/>
                    <measurement group_id="B3" value="55" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of Acute Respiratory Distress Syndrome (ARDS)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Sepsis with pneumonia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sepsis without pneumonia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pneumonia without sepsis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Aspiration only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arterial pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="10"/>
                    <measurement group_id="B2" value="76" spread="9"/>
                    <measurement group_id="B3" value="75" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking vasopressors at the time of infusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA)</title>
          <description>SOFA score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems which are added up. Each score ranges from 0 to 4. SOFA score ranges from 0 (best) to 24 (worst).</description>
          <population>Data not recorded in one patient treated with Plasma-Lyte A (placebo).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="3.3"/>
                    <measurement group_id="B2" value="6.9" spread="2.7"/>
                    <measurement group_id="B3" value="7.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) III score</title>
          <description>The range of APACHE III is from 0 to 299. The higher score, the worse clinical outcome.</description>
          <population>Data not recorded in one patient treated with Plasma-Lyte (placebo).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104" spread="31"/>
                    <measurement group_id="B2" value="89" spread="33"/>
                    <measurement group_id="B3" value="99" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minute ventilation</title>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="3.2"/>
                    <measurement group_id="B2" value="9.6" spread="2.4"/>
                    <measurement group_id="B3" value="10.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory rate</title>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="6.6"/>
                    <measurement group_id="B2" value="24.5" spread="6.3"/>
                    <measurement group_id="B3" value="26.7" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tidal volume</title>
          <population>Data not recorded in one patient treated with hMSCs.</population>
          <units>mL/kg predicted body weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3" spread="0.9"/>
                    <measurement group_id="B2" value="6.1" spread="0.7"/>
                    <measurement group_id="B3" value="6.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean airway pressure</title>
          <population>Data not recorded in three patients treated with hMSCs and one patient treated with Plasma-Lyte A (placebo).</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.8" spread="4.9"/>
                    <measurement group_id="B2" value="16.4" spread="3.6"/>
                    <measurement group_id="B3" value="17.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plateau airway pressure</title>
          <population>15 patients did not have baseline plateau pressure recorded.</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="5.7"/>
                    <measurement group_id="B2" value="23.7" spread="5.1"/>
                    <measurement group_id="B3" value="25.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive end-expiratory pressure (PEEP)</title>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="3.7"/>
                    <measurement group_id="B2" value="10.8" spread="2.6"/>
                    <measurement group_id="B3" value="11.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Driving pressure</title>
          <population>Data not recorded in 10 patients treated with hMSCs and in 5 patients treated with Plasma-Lyte (placebo).</population>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.0" spread="4.1"/>
                    <measurement group_id="B2" value="12.5" spread="4.3"/>
                    <measurement group_id="B3" value="13.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PaO2/FiO2</title>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.1" spread="4.3"/>
                    <measurement group_id="B2" value="19.1" spread="5.2"/>
                    <measurement group_id="B3" value="18.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oxygenation index</title>
          <description>Oxygenation index calculated as: FiO2 (%) x Mean Airway Pressure / PaO2</description>
          <population>Data not recorded in 3 patients treated with hMSCs and 1 patient treated with Plasma-Lyte (placebo).</population>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.1" spread="45.9"/>
                    <measurement group_id="B2" value="95.7" spread="41.2"/>
                    <measurement group_id="B3" value="103.9" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lung injury score (LIS)</title>
          <description>LIS is a composite 4-point scoring system including the PaO2/FiO2, PEEP, lung compliance, and the extent of infiltrates on the chest X-ray. Each of the four components is categorized from 0 to 4, where a higher number is worse. The total Lung Injury Score is obtained by dividing the aggregate sum by the number of components used.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="0.4"/>
                    <measurement group_id="B2" value="3.0" spread="0.5"/>
                    <measurement group_id="B3" value="3.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ventilation mode</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Volume control</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pressure-regulated volume control</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion</title>
        <description>Within 6 h of study product infusion:
Increase in vasopressor dose to the following values or higher:
Norepinephrine 10 μg/min
Phenylephrine 100 μg/min
Dopamine 10 μg/kg per min
Epinephrine 0.1 μg/kg per min or addition of a third vasopressor
New ventricular tachycardia, ventricular fibrillation or asystole
New cardiac arrhythmia requiring cardioversion
Hypoxaemia requiring an increase in FiO2 of 0·2 or more and an increase in PEEP of 5·0 or more to maintain SpO2 in the target range of 88-95%
Clinical scenario consistent with transfusion incompatibility or transfusion-related infection (eg, urticaria, new bronchospasm)</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells (hMSCs)</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A (Placebo)</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion</title>
          <description>Within 6 h of study product infusion:
Increase in vasopressor dose to the following values or higher:
Norepinephrine 10 μg/min
Phenylephrine 100 μg/min
Dopamine 10 μg/kg per min
Epinephrine 0.1 μg/kg per min or addition of a third vasopressor
New ventricular tachycardia, ventricular fibrillation or asystole
New cardiac arrhythmia requiring cardioversion
Hypoxaemia requiring an increase in FiO2 of 0·2 or more and an increase in PEEP of 5·0 or more to maintain SpO2 in the target range of 88-95%
Clinical scenario consistent with transfusion incompatibility or transfusion-related infection (eg, urticaria, new bronchospasm)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion</title>
        <description>Within 24 h of study product infusion
• Any cardiac arrest or death</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells (hMSCs)</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A (Placebo)</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion</title>
          <description>Within 24 h of study product infusion
• Any cardiac arrest or death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)</title>
        <description>Safety endpoint: Any unexpected severe adverse events in two groups</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)</title>
          <description>Safety endpoint: Any unexpected severe adverse events in two groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PaO2:FiO2 Change From Baseline to Day 3</title>
        <description>Efficacy endpoint: PaO2:FiO2 change from baseline to day 3</description>
        <time_frame>baseline and day 3</time_frame>
        <population>The values of PaO2:FiO2 were not available in 10 patients treated with hMSCs and in 2 patients treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>PaO2:FiO2 Change From Baseline to Day 3</title>
          <description>Efficacy endpoint: PaO2:FiO2 change from baseline to day 3</description>
          <population>The values of PaO2:FiO2 were not available in 10 patients treated with hMSCs and in 2 patients treated with placebo.</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="-1.2" upper_limit="10.8"/>
                    <measurement group_id="O2" value="3.5" lower_limit="-2.7" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Injury Score From Baseline to Day 3</title>
        <description>Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.</description>
        <time_frame>baseline and day 3</time_frame>
        <population>The values were missing in 9 hMSC patients and 2 placebo patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Injury Score From Baseline to Day 3</title>
          <description>Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.</description>
          <population>The values were missing in 9 hMSC patients and 2 placebo patients.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-1.00" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.33" lower_limit="-0.67" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation Index Change From Baseline to Day 2</title>
        <description>Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2</description>
        <time_frame>baseline and day 2</time_frame>
        <population>The values were missing in 16 patients treated by MSC and 6 patients treated by placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation Index Change From Baseline to Day 2</title>
          <description>Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2</description>
          <population>The values were missing in 16 patients treated by MSC and 6 patients treated by placebo</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" lower_limit="-67.9" upper_limit="14.9"/>
                    <measurement group_id="O2" value="-19.5" lower_limit="-47.8" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SOFA Score Change From Baseline to Day 3</title>
        <description>Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.</description>
        <time_frame>baseline and day 3</time_frame>
        <population>The values were missing in 3 MSC patients and 1 placebo patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>SOFA Score Change From Baseline to Day 3</title>
          <description>Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.</description>
          <population>The values were missing in 3 MSC patients and 1 placebo patient.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-4" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Death to Day 28</title>
        <description>Efficacy endpoint: all-cause mortality at day 28</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Death to Day 28</title>
          <description>Efficacy endpoint: all-cause mortality at day 28</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality to Day 60</title>
        <description>Efficacy endpoint: all-cause mortality at day 60</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality to Day 60</title>
          <description>Efficacy endpoint: all-cause mortality at day 60</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ventilator-free Days to Day 28</title>
        <description>Efficacy endpoint: Number of ventilator-free days to day 28.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ventilator-free Days to Day 28</title>
          <description>Efficacy endpoint: Number of ventilator-free days to day 28.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O2" value="17" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-pulmonary Organ-failure-free Days to Day 28</title>
        <description>Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-pulmonary Organ-failure-free Days to Day 28</title>
          <description>Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiopoietin 2 Change From Baseline to 6 h</title>
        <description>Biological markers of endothelial injury: angiopoietin 2</description>
        <time_frame>baseline and 6 hours</time_frame>
        <population>The biomarker values were missing in one patient treated with hMSC and one patient treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiopoietin 2 Change From Baseline to 6 h</title>
          <description>Biological markers of endothelial injury: angiopoietin 2</description>
          <population>The biomarker values were missing in one patient treated with hMSC and one patient treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1120" lower_limit="-4706" upper_limit="-66"/>
                    <measurement group_id="O2" value="287" lower_limit="-1005" upper_limit="2374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiopoietin 2 Change From Baseline to 24 h</title>
        <description>Biological markers of endothelial injury: angiopoietin 2</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Angiopoietin 2 Change From Baseline to 24 h</title>
          <description>Biological markers of endothelial injury: angiopoietin 2</description>
          <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2080" lower_limit="-6404" upper_limit="47"/>
                    <measurement group_id="O2" value="-537" lower_limit="-4294" upper_limit="1029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 6 Change From Baseline to 6 h</title>
        <description>Biological markers of inflammation: interleukin 6</description>
        <time_frame>baseline and 6 hours</time_frame>
        <population>The values were not available in one patient treated with hMSC and one patient treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 6 Change From Baseline to 6 h</title>
          <description>Biological markers of inflammation: interleukin 6</description>
          <population>The values were not available in one patient treated with hMSC and one patient treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51" lower_limit="-124" upper_limit="4"/>
                    <measurement group_id="O2" value="-20" lower_limit="-71" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 6 Change From Baseline to 24 h</title>
        <description>Biological markers of inflammation: interleukin 6</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 6 Change From Baseline to 24 h</title>
          <description>Biological markers of inflammation: interleukin 6</description>
          <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34" lower_limit="-137" upper_limit="4"/>
                    <measurement group_id="O2" value="-43" lower_limit="-165" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 8 Change From Baseline to 6 h</title>
        <description>Biological markers of inflammation: interleukin 8</description>
        <time_frame>baseline and 6 hours</time_frame>
        <population>The values were not available in one patient treated with hMSC and one patient treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 8 Change From Baseline to 6 h</title>
          <description>Biological markers of inflammation: interleukin 8</description>
          <population>The values were not available in one patient treated with hMSC and one patient treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-24" upper_limit="3"/>
                    <measurement group_id="O2" value="-1" lower_limit="-8" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 8 Change From Baseline to 24 h</title>
        <description>Biological markers of inflammation: interleukin 8</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 8 Change From Baseline to 24 h</title>
          <description>Biological markers of inflammation: interleukin 8</description>
          <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" lower_limit="-34" upper_limit="4"/>
                    <measurement group_id="O2" value="-5" lower_limit="-17" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RAGE Change From Baseline to 6 h</title>
        <description>Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)</description>
        <time_frame>baseline and 6 hours</time_frame>
        <population>The values were not available in one patient treated with hMSC and one patient treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>RAGE Change From Baseline to 6 h</title>
          <description>Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)</description>
          <population>The values were not available in one patient treated with hMSC and one patient treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-326" lower_limit="-888" upper_limit="-45"/>
                    <measurement group_id="O2" value="-322" lower_limit="-624" upper_limit="-93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RAGE Change From Baseline to 24 h</title>
        <description>Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)</description>
        <time_frame>baseline and 24 hours</time_frame>
        <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Mesenchymal Stem Cells</title>
            <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Plasma-Lyte A</title>
            <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>RAGE Change From Baseline to 24 h</title>
          <description>Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)</description>
          <population>The values were not available in two patients treated with hMSC and two patients treated with placebo.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-393" lower_limit="-1118" upper_limit="-78"/>
                    <measurement group_id="O2" value="-411" lower_limit="-1057" upper_limit="-110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <desc>All-cause mortality by day 60 after study product infusion
Serious adverse events, expected and unexpected, also included any deaths through study day 28 (none of them were related to study product or study procedures per DSMB review)
Please see our Lancet Resp Medicine 2018 publication (citation included) for further details including adjusted analyses of baseline differences between the MSC and placebo treated groups</desc>
      <group_list>
        <group group_id="E1">
          <title>Human Mesenchymal Stem Cells</title>
          <description>A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.
Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.</description>
        </group>
        <group group_id="E2">
          <title>Plasma-Lyte A</title>
          <description>A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.
Plasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Calvarial bone marrow abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heart block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to multi-organ failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hospital readmission due to pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to worsening respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Worsening respiratory failure, recovered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospital readmission due to post-surgical pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fecal and urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A. Matthay, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-502-7434</phone>
      <email>michael.matthay@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

